Today: 9 June 2026
Bitcoin Price Nears $80,000 Again as ETF Cash Returns — What Could Stop the Rally
24 April 2026
2 mins read

Bitcoin Price Nears $80,000 Again as ETF Cash Returns — What Could Stop the Rally

London, April 24, 2026, 11:04 BST

Bitcoin hovered under $78,000 on Friday, propped up by fresh inflows into U.S.-listed spot Bitcoin funds, while global markets remained unsettled by oil, dollar moves, and Middle East jitters. BTC was changing hands near $77,500, after swinging from a session high of $78,600 down to $77,068.

This isn’t just crypto traders piling in; listed funds are behind the bid. A spot Bitcoin ETF lets investors tap into Bitcoin via standard brokerage accounts, skipping direct ownership of the token.

Demand has come surging back at a complicated moment. U.S.-listed Bitcoin ETFs pulled in $223.3 million on April 23, following a $335.8 million haul just the day before, according to Farside Investors data. The inflows keep flowing, keeping Bitcoin hovering close to that $80,000 mark.

The wider backdrop looked murkier. The dollar headed toward its first weekly advance in three weeks. Brent crude pushed up to $106.60 a barrel, with traders on edge as stalled U.S.-Iran negotiations and fresh doubts around the Strait of Hormuz lingered. Bitcoin hovered, not far from flat, at $77,895.85, according to Reuters’ currency markets report.

Bitcoin managed to edge past $79,000 on Wednesday, heading for its fourth straight weekly gain, according to Investing.com. ETF inflows have given prices a lift, though the advance has been tempered by rising oil prices and a stronger dollar. Traders are watching the $80,000 mark—not so much for headlines now, but to see if fund demand can keep up with those looking to cash out.

Akshat Siddhant, lead quant analyst at Mudrex, pointed to robust ETF inflows and dwindling exchange reserves as drivers behind Bitcoin’s climb. Fewer coins sitting on exchanges—essentially, lower reserves—typically signals a thinner selling side, traders say.

Giottus CEO Vikram Subburaj pegged Bitcoin’s short-term test squarely in the mid-$77,000 range, dubbing that level its “short-term equilibrium band.” According to Subburaj, it’s institutional appetite, not a retail surge, that’s fueling the current momentum. The Economic Times

Bitcoin’s mood didn’t spread to its rivals. Spot Ethereum ETFs posted a $75.9 million outflow on April 23, snapping a 10-day inflow run. Ether dropped roughly 1.8% in the span of 24 hours, changing hands around $2,317, according to SoSoValue data cited by Blockhead.

The rally may look strong on the surface, but there’s less depth underneath. CoinSwitch Markets Desk pointed out that while Bitcoin surged toward $79,000, the bulk of that action was fueled by futures trading—not consistent spot demand. Futures, those contracts for wagering on price direction, tend to amplify swings, especially when traders start closing out positions.

Crypto isn’t dodging the scrutiny from macro traders. BMO’s chief FX strategist Mark McCormick warns the coming three to six months won’t look like the “pre-conflict normal.” He points out that “drawdown risk is rising” and says traditional cross-asset signals are breaking down. Reuters

Bitcoin’s holding steady for the moment, sidestepping a sharper retreat. A clear push through $80,000—and ETF inflows staying in the green—would mark the straightforward route. On the flip side, slipping below the mid-$77,000 zone leaves the door open for oil, the dollar, or shifting derivatives to set the tone.

Stock Market Today

  • Proxy Adviser Supports Nanoco Group's Plan to Delist from LSE
    June 9, 2026, 9:17 AM EDT. Nanoco Group PLC, a nanotechnology firm, announced that independent proxy adviser Glass Lewis has recommended shareholders approve the company's resolution to delist from the London Stock Exchange (LSE). The move signals a significant shift for Nanoco, potentially changing its trading and regulatory environment. Shareholder approval for such a resolution typically permits a company to withdraw its shares from public exchange trading, often to pursue private ownership or alternative funding routes. This development follows Nanoco's strategic review and may impact investor access and share liquidity. The recommendation by Glass Lewis adds weight to the proposal ahead of the upcoming shareholder vote.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
FTSE 100 Falls Today as Oil Surge and Trump Tariff Threat Shake London Stocks
Previous Story

FTSE 100 Falls Today as Oil Surge and Trump Tariff Threat Shake London Stocks

FirstEnergy Ohio Bills Could Rise Up To $5 A Month As May 22 Rate Filing Nears
Next Story

FirstEnergy Ohio Bills Could Rise Up To $5 A Month As May 22 Rate Filing Nears

Go toTop